Exploring whether Benzalkonium Chloride could be effective against SARS-CoV-2
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Exploring whether Benzalkonium Chloride could be effective against SARS-CoV-2

10 Mar 2021 (Last Updated March 18th, 2021 11:50)

Sponsored by Novo Nordisk pharmatech Sponsored by Visit Company
Exploring whether Benzalkonium Chloride could be effective against SARS-CoV-2
Credit: Krasula / Shutterstock.

Quaternary ammonium compounds (Quats) are membrane-active agents well known for their efficacy against bacteria, fungi, algae, and enveloped viruses. A popular example is Benzalkonium Chloride (BKC), an antiseptic ingredient often formulated in topical, ophthalmic, nasal and oral preparations.

By deactivating viruses through the disruption of lipid membranes, BKC is effective against a long list of enveloped viruses, including enteroviruses, rotaviruses, norovirus, influenza virus, severe acute respiratory syndrome coronavirus (SARS-CoV), rhinovirus, chlamydia, herpes simplex and hepatitis A.

As the need for effective yet safe antiviral products intensifies amid the Covid-19 pandemic, what is BKC’s virucidal effect when it comes to coronaviruses?

How does Benzalkonium Chloride (BKC) deactivate viruses?

In the mode of action, the cationic ‘headgroup’ of BKC is progressively adsorbed to the negatively charged phosphate heads of phospholipids in the lipid bilayer and subsequently increases in concentration. The consistent increase of BKC concentration results in reduced membrane fluidity, creating hydrophilic gaps in the membrane.

In addition, the alkyl chain ‘tail’ component of BKC further perturbs the membrane bilayer by permeating the barrier and disrupting its physical and biochemical properties. Protein function is subsequently disturbed, and the combination of these effects results in the solubilisation of the bilayer constituents into BKC/phospholipid micelles. BKC also interrupts inter-cellular targets and compromises the conformational behaviour of DNA.

BKC and coronaviruses

Multiple studies have reported on the virucidal effect of BKC against coronaviruses. Rabenau et al. found that, as a surface disinfectant in concentration of 0.5%, BKC demonstrated a reduction factor of >4 against SARS-CoV. Meanwhile, by evaluating the virucidal activity of different oral rinses against three strains of SARS-CoV-2, Meister et al. reported log reductions of >3.11, >2.78 and >2.61 for a rinse containing 0.035% BKC.

While Schrank et al. has stated that the cumulated data on BKC-based products against the family of coronaviruses is not uniformly asserted, Quats are indeed reported to be effective against influenza viruses. Due to the similarities between the outer membrane structures of influenza and SARS-CoV-2 viruses with their relatively comparable phospholipid bilayers, Schrank et al. concludes significant ground for the potential efficacy of BKC against SARS-CoV-2.

Quats and BKC in the healthcare sector

Quats-based disinfectants have been recommended by several government agencies for deactivating SARS-CoV-2 virus. Of the US Environmental Protection Agency’s list of 370 suitable disinfectant products for use against SARS-CoV-2, a total 171 (40%) contain Quats ingredients alone, while a further 33 products contain Quats alongside one other class of active ingredient. The US CDC also asserted Quats to be a proven disinfectant, meanwhile Benzalkonium Chloride remains on the FDA’s list of approved hand sanitiser active ingredients.

In times like these, disinfection has never been more important in healthcare settings, where alcohol-based hand sanitisers (ABHS) predominate due to their low cost. However, the flammable compounds in ABHS offer just momentary disinfection, with frequent use often harsh and drying on the skin. Longer lasting effects are provided by less volatile active compounds such as Quats, which are also kinder to skin.

Free Whitepaper

Is recombinant insulin a factor to consider for viral production?

Recombinant insulin is a key component in serum free growth media for mammalian cells, and plays an important role in the manufacturing of monoclonal antibodies and other biological drug products approved by regulatory bodies worldwide. But how does it perform as a growth factor for lentivirus and adeno-associated virus (AAV) serotypes?

Insulin Human AF is the high-quality recombinant insulin product supplied by Novo Nordisk Pharmatech. At Cell UK this year, the company presented the results of a study investigating the effects of different Insulin Human AF concentrations and addition times on cell growth and viral expression. Download for a detailed copy of the results.

By clicking the “Submit” button above, you accept and acknowledge that your data will be used as described in the Novo Nordisk Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.